N/A
N=6,525
Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade Via E-learning
Neuromuscular Blockade
Bottom Line
View on ClinicalTrials.gov: NCT02925143 ↗Enrolled (actual)
6,525
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) (Yes/no) — 1425 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- E-learning course in neuromuscular monitoring (Other)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Herlev Hospital
- Primary completion
- Jun 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) (Yes/no) |
1425 | — |
| PRIMARY Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing NMBA (Yes/no) |
3172 | — |
| SECONDARY Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA |
95.23 | — |
| SECONDARY Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no) |
85 | — |
| SECONDARY Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no) |
2047 | — |
| SECONDARY Administration of More Than One Reversal Agent in Cases Receiving a Non-depolarizing NMBA (Yes/no) |
213 | — |
| SECONDARY Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA |
100 | — |
Summary
To assess the impact of an e-learning course in neuromuscular monitoring on the frequency of application of objective neuromuscular monitoring for assessment of depth of neuromuscular blockade in general anaesthesia and secondarily on the incidence of residual neuromuscular blockade after anesthesia.
We will collect data prospectively from 6 Danish anaesthesia departments from the time of intervention, using data from the Anaesthesia Information Management System (AIMS). Baseline data is obtained from another study based on the same data extraction procedure (NCT02914119).
Eligibility Criteria
Inclusion Departments We will include the 6 largest anaesthesia departments in the Zealand Region of Denmark.
Anaesthetists We will include the following anaesthesia personnel as anaesthetists: nurse anaesthetists in training, nurse anaesthetists, first year residents in anaesthesiology, residents in the last 4 years of training in anaesthesiology, and specialist consultants in anaesthesia.
Patients We will include and collect data from all patients undergoing general anaesthesia with neuromuscular blockade in each data collection period. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses with a case for every general anaesthetic received.
Exclusion criteria We will exclude personnel without clinical functions, i.e. administrative personnel.
Data sourced from ClinicalTrials.gov (NCT02925143). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.